Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE program with Gilead’s person-centric approach in mind to reach underserved communities and groups around the world.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
Maria underwent many more medical tests until a fibroscan conducted in 2018 by a hepatologist revealed that she had a rare autoimmune liver disease called primary biliary cholangitis, or PBC.
Gilead Sciences, Inc. and the Elton John AIDS Foundation announced a five-year extension of the RADIAN ® partnership to help meet the needs of the most vulnerable key populations in Eastern Europe and Central Asia (EECA) where the HIV epidemic is growing.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...